Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-337 in Advanced Solid Tumors
NCT06093698Phase 1Not yet recruiting
- Sponsor
- ITabMed Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
01
Overview
Phase 1, open-label trial of A-337 in solid tumor (advanced stage), sponsored by ITabMed Ltd. Primary endpoints: Incidence and Characteristics of Adverse Events and Maximum Tolerated Dose and Dose Limiting Toxicity. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
A-337
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06093698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093698.